Immunologic changes point to potential for clinical investigation of combination immunotherapy for deadly kidney cancer

March 29, 2017

Immunologic changes observed in an early study of patients with metastatic renal cell carcinoma (MRCC) raised the possibility for a larger clinical study of combination immunotherapy, according to findings reported by researchers at The University of Texas MD Anderson Cancer Center.

The results of an open-label pilot study comparing combinations of anti-PD1 (nivolumab) alone, or in combination with either anti-CTLA-4 (ipilimumab) or anti-VEGF (bevacizumab) therapies, revealed "promising clinical activities" in MRCC patients. Results will be presented April 4 in a poster session at the annual meeting of the American Association of Cancer Research in Washington, D.C.

In this study of 60 patients, 44 were "evaluable" for clinical responses for at least 12 weeks. The combination of nivolumab plus bevacizumab, a drug that inhibits tumor blood vessel formation, appeared to result in the highest response rate in the study, with 53 percent (10 of 19) of patients experiencing either a complete or partial response. This group also reported higher levels of adverse effects, but a substantial percentage was due to bevacizumab-related hypertension easily controlled by standard medications.

"This trial was aimed at getting pre- and post- treatment samples to evaluate immune responses in patients in order to understand potential mechanisms of response and resistance that may be common or unique," said Padmanee Sharma, M.D., Ph.D., professor of Genitourinary Medical Oncology. "Immune and molecular correlative studies may allow us to identify novel biomarkers that can be used for correlation with clinical outcomes in MRCC patients."

Immune checkpoint blockade, including anti-CTLA-4 and anti-PD1 as monotherapies, have been known to have clinical activity against MRCC but with relatively low clinical response rates. Bevacizumab is a standard therapy for MRCC but also has a low response rate. The researchers hypothesized that combination therapies could lead to measurable immunological changes and improved clinical activity.

The pre-surgical/pre-biopsy trial included adult patients with MRCC who had no prior treatment with ipilimumab, nivolumab or bevacizumab. The patients were enrolled and stratified by planned surgical procedure or biopsy and randomized to receive nivolumab alone, nivolumab plus bevacizumab, or nivolumab plus ipilimumab. The therapies were followed by surgical removal of tumors or post-treatment biopsies. Patients were then placed on nivolumab maintenance therapy for up to two years depending on disease progression and/or treatment intolerance. Pre- and post-treatment blood and tumor samples were obtained for monitoring of immune and molecular correlates to clinical activities. Patients were followed for a median duration of 17 weeks ranging from three to 85 weeks as of Dec. 16, 2016.

"Out of 60 patients treated, 44 were evaluable for clinical responses post-treatment and/or procedures," said Jianjun Gao, M.D., Ph.D., assistant professor of Genitourinary Medical Oncology. "We observed a response rate of 53 percent for patients treated with nivolumab plus bevacizumab."

The study also revealed a 38 percent response rate for those who received nivolumab plus ipilimumab, while patients receiving nivolumab monotherapy had a 42 percent response rate and treatment was generally well tolerated with mostly grade 1 or 2 adverse events. Grade 3 or higher toxicities were 19 percent for nivolumab alone, 41 percent for nivolumab plus bevacizumab, and 27 percent in the nivolumab plus ipilimumab group."

Study findings showed that the patient group receiving nivolumab alone had a stable disease rate of 33 percent with 25 percent experiencing disease progression. Patients receiving nivolumab plus bevacizumab had a 16 percent stable disease and disease progression rates, while 16 percent of participants withdrew from the study. Of those who received nivolumab plus ipilimumab, 8 percent had stable disease rates,38 percent experienced disease progression and 15 percent withdrew from the trial.

"These findings are significant since a signal to indicate efficacy for the nivolumab plus bevacizumab arm could provide data to design a larger study," said Sharma.
-end-
Study team members included Jose Karam, M.D., Christopher Wood, M.D., and Surena Matin, M.D., all of the Department of Urology; Kamran Arhar, M.D., Interventional Radiology; Eric Jonasch, M.D., Nizar Tannir, M.D., and Matthew Campbell, M.D., Genitourinary Medical Oncology; Chaan Ng, M.D, Ph.D., Radiology; Rebecca Slack, Biostatistics; Priya Rao, M.D, Pathology; James Allison, Ph.D., Jorge Blando, D.V.M., Luis Vence, Ph.D., Sreyashi Basu, Ph.D., Hao Zhao, Ph.D., and Hong Chen, Immunology; and Tenghui Chen, Ph.D., Bioinformatics and Computational Biology.

The study was funded by the National Institutes of Health (NCT02210117) and Bristol-Myers Squibb.

University of Texas M. D. Anderson Cancer Center

Related Bevacizumab Articles from Brightsurf:

Response to adjuvant bevacizumab among patients with resected melanoma may vary by age
Younger patients with resected melanoma had some benefit from adjuvant treatment with the anti-VEGF therapeutic bevacizumab (Avastin) while older patients with resected melanoma did not.

Researchers identify genetic variants linked to toxic side effects from bevacizumab
In the largest study of its kind, researchers have found two common genetic variants that can be used to predict whether or not cancer patients might suffer severe adverse side-effects, such as high blood pressure, from the drug bevacizumab.

Training the immune system to fight ovarian cancer
A personalized cancer vaccine safely and successfully boosted immune responses and increased survival rates in patients with ovarian cancer, according to results from a pilot clinical trial.

The use of immunotherapy to treat metastatic breast cancer
The Authors review immunotherapy attempts to treat metastatic breast cancer.

New and highly sensitive ELISA technique for bioanalysis of bevacizumab
Bevacizumab is an anti-growth factor vascular endothelial growth factor (VEGF) monoclonal antibody, it is the antiangiogenic agent at the most advanced stage of development in the treatment of NSCLC.This drug was selected because of its inter individual differences in clinical response, its therapeutic importance in the treatment of non-small cell lung cancer (NSCLC).

Bevacizumab dramatically improves severe hereditary hemorrhagic telangiectasia (HHT) associated bleeding
Patients with hereditary hemorrhagic telangiectasia (HHT) with severe bleeding, who were treated with intravenous bevacizumab, reported a marked reduction in nose bleeds and gastrointestinal bleeding and were able to stop or considerably reduce blood transfusions, resulting in significantly improved quality of life.

Study shows new second line therapy for metastatic colorectal cancer is effective and safe
A randomised trial in 650 patients has confirmed the safety and efficacy of a new second line treatment for metastatic colorectal cancer, researchers report at the ESMO Asia 2017 Congress.

Cheaper drug could release more than £13.5 million a year within the next 5 years for other services
Doctors in the northeast of England face legal action from two of the world's largest pharmaceutical companies for offering patients with a serious eye condition the choice of a safe, effective but much cheaper drug, reports The BMJ today.

PET/CT helps predict therapy effectiveness in pediatric brain tumors
In this first ever molecular drug-imaging study in children, researchers in The Netherlands used whole-body positron emission tomography/computed tomography (PET/CT) scans to determine whether bevacizumab (Avastin) treatment of diffuse intrinsic pontine glioma (DIPG) in children is likely to be effective.

Immunologic changes point to potential for clinical investigation of combination immunotherapy for deadly kidney cancer
Immunologic changes observed in an early study of patients with metastatic renal cell carcinoma (MRCC) raised the possibility for a larger clinical study of combination immunotherapy, according to findings reported by researchers at The University of Texas MD Anderson Cancer Center.

Read More: Bevacizumab News and Bevacizumab Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.